IBI-130
- Generic Name
- IBI-130
A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 182
- Registration Number
- NCT05923008
- Locations
- 🇦🇺
Sunshine Coast University, Birtinya, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath